3MM Stock Chart & Stats
€1.76
€0.04(2.63%)
At close: 4:00 PM EDT
€1.76
€0.04(2.63%)
Day’s Range― - ―
52-Week Range€0.68 - €2.20
Previous CloseN/A
Volume0.00
Average Volume (3M)67.00
Market Cap
€10.95M
Enterprise Value€38.08
Total Cash (Recent Filing)€1.34M
Total Debt (Recent Filing)€19.00M
Price to Earnings (P/E)242.0
Beta0.60
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding14,609,619
10 Day Avg. Volume100
30 Day Avg. Volume67
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-0.87
Price to Sales (P/S)3.81
P/FCF Ratio-5.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.47
Revenue Forecast (FY)€6.60M
Bulls Say, Bears Say
Bulls Say
Rare-disease SpecializationAdvicenne operates in specialized rare-disease markets where focused clinical expertise and approved therapies can support differentiated positioning. Its marketed Sibnayal product gives the company an established commercial platform rather than relying only on early-stage pipeline development.
Improving Gross ProfitabilityThe shift to positive gross margin indicates that product economics improved over time, creating a more viable foundation for future scale. Although operating profitability remains negative, better gross profitability could support stronger contribution from additional sales and geographic commercialization.
Multiple Commercialization ChannelsAdvicenne can monetize its therapies through direct product revenue as well as partner-based arrangements such as milestones and royalties. This channel diversity may broaden geographic reach and reduce dependence on a single commercialization route as approved products expand.
Bears Say
Persistent UnprofitabilityPersistent operating and net losses show that current revenue does not yet cover the company’s cost base. Without sustained improvement in scale or profitability, Advicenne may remain reliant on funding or business development proceeds, limiting durable earnings visibility.
Stressed Balance SheetNegative equity materially weakens financial resilience and reduces flexibility to absorb setbacks or invest internally. Sizable debt relative to the asset base further signals a fragile capital structure, increasing pressure on future financing and capital allocation decisions.
Ongoing Cash BurnRepeated negative operating and free cash flow indicates that the business has not yet become self-funding. The renewed deterioration in 2025 increases dependence on external capital, which can constrain growth plans and amplify financial risk over the next several quarters.
Advicenne SA News
3MM FAQ
What was Advicenne SA’s price range in the past 12 months?
Advicenne SA lowest stock price was €0.68 and its highest was €2.20 in the past 12 months.
What is Advicenne SA’s market cap?
Advicenne SA’s market cap is €10.95M.
When is Advicenne SA’s upcoming earnings report date?
Advicenne SA’s upcoming earnings report date is Apr 01, 2027 which is in 186 days.
How were Advicenne SA’s earnings last quarter?
Advicenne SA released its earnings results on Sep 17, 2026. The company reported €0.32 earnings per share for the quarter.
Is Advicenne SA overvalued?
According to Wall Street analysts Advicenne SA’s price is currently Overvalued.
Does Advicenne SA pay dividends?
Advicenne SA does not currently pay dividends.
What is Advicenne SA’s EPS estimate?
Advicenne SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Advicenne SA have?
Advicenne SA has 14,609,619 shares outstanding.
What happened to Advicenne SA’s price movement after its last earnings report?
Advicenne SA reported an EPS of €0.32 in its last earnings report. Following the earnings report the stock price went up 2.329%.
Which hedge fund is a major shareholder of Advicenne SA?
Currently, no hedge funds are holding shares in DE:3MM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Advicenne SA
Advicenne S.A. operates as a specialized pharmaceutical firm, focusing on the innovation and commercialization of therapeutic solutions for various kidney-related disorders. The company's primary offering, Sibnayal, targets both distal renal tubular acidosis and cystinuria. Established in 2007, Advicenne S.A. maintains its principal offices in Paris, France.